Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.45 |
| ▸ | CA7 | P43166 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 13/20 | 0.44 |
| ▸ | CA12 | O43570 | 10/20 | 0.44 |
| ▸ | CA1 | P00915 | 12/20 | 0.44 |
| ▸ | CA6 | P23280 | 3/20 | 0.39 |
| ▸ | CA5A | P35218 | 3/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19386070 | 0.81 | CA2 (0.35) | CA2CA7CA9CA12CA1 | |
| SCHEMBL1080710 | 0.80 | CA2 (0.32) | CA2CA7CA9CA12CA1 | |
| SCHEMBL3477728 | 0.74 | CA1 (0.37) | CA2CA7CA9CA12CA1 | |
| SCHEMBL19386069 | 0.73 | HTR6 (0.31) | — | |
| SCHEMBL2282741 | 0.71 | NPC1 (0.45) | — | |
| SCHEMBL3673621 | 0.71 | CA2 (0.44) | CA2CA7CA9CA12CA1 | |
| SCHEMBL2578681 | 0.70 | LMNA (0.40) | — | |
| SCHEMBL1423112 | 0.70 | KDM4E (0.41) | CA2CA1 | |
| SCHEMBL11209740 | 0.69 | CA2 (0.45) | CA2CA7CA9CA12CA1 | |
| SCHEMBL28919292 | 0.68 | CA2 (0.44) | CA2CA7CA9CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013009810-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | claimed |
| WO-2013009830-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | claimed |
| EP-2451285-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-05-16 | — | — | EP | claimed |
| WO-2011005608-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-01-13 | — | — | WO | claimed |
| WO-2019171234-A9 | HETEROCYCLIC COMPOUNDS AS FUNGICIDES | PI INDUSTRIES LTD. (IN) | 2020-01-09 | — | — | WO | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013009810-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
| WO-2013009830-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
| EP-2533783-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| EP-2193125-A2 | OXADIAZOLE DERIVATIVES | Merck Serono S.A. (CH) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |